



Symposium

HEMATOLOGICAL MALIGNANCIES

From Mechanisms to Therapy

9th - 12th March, 2016

IEO, via Ripamonti 435
IEO at Campus, via Adamello 16
Milan, Italy

INTRODUCTION

As the field of onco-hematology is constantly, often turbulently, evolving, the promotion of meetings that allow researchers to compare and share information, transferring acquisitions obtained from the study of the genome to the bedside, is crucial and can lead to the development of innovative personalized treatments with highest therapeutic effect and lowest toxicity burden. In this context, we believe that a discussion on the state of the art of blood and lymphatic tissue cancers could represent an important scientific, cultural and informative contribution of the national and international medical community, in the year in which the World Health Organization is preparing to publish guidelines for the - increasingly molecular - diagnosis and treatment of such conditions.

SCIENTIFIC COMMITTEE

Francesco Bertolini,
European Institute of Oncology, Milan, Italy
Riccardo Dalla Favera,
Columbia University, New York, New York, USA
Francesco Lo Coco,
Università Tor Vergata, Rome, Italy
Pier Giuseppe Pelicci,
European Institute of Oncology, Milan, Italy
Stefano A. Pileri,
European Institute of Oncology, Milan, Italy
Corrado Tarella,
European Institute of Oncology, Milan, Italy

KEYNOTE LECTURERS

Michael Stratton,
Wellcome Trust Sanger Institute, Hinxton, UK
Stefano A. Pileri,
European Institute of Oncology, Milan, Italy
Felice Bombaci,
Patient Advocate, Gruppo AIL Pazienti
Leucemia Mieloide Cronica, Rome, Italy

GUEST SPEAKERS

Ranjana Hira Advani, Stanford School of Medicine, Stanford, USA
Frederick Alt, Harvard University, Boston, USA
Scott A. Armstrong, Memorial Sloan Kettering Cancer Center, New York, USA
Fernando Camargo, Harvard University, Boston, USA
Mario Cazzola, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
Carlo M. Croce, The Ohio State University, Columbus, USA
Riccardo Dalla Favera, Columbia University, New York, New York, USA
John E. Dick, University Health Network, Toronto, Canada
Hartmut Döhner, University of Ulm, Ulm, Germany
Brunangelo Falini, University of Perugia, Perugia, Italy
Adolfo A. Ferrando, Columbia University, New York, New York, USA
Guillermo Garcia-Manero, MD Anderson Cancer Center, Houston, USA
Randy D. Gascoyne, BC Cancer Agency, Vancouver, Canada
Philippe Gaulard, INSERM, Créteil, France
Elaine S. Jaffe, National Cancer Institute, Bethesda, USA
Carl H. June, University of Pennsylvania, Philadelphia, USA
Michael J. Keating, MD Anderson Cancer Center, Houston, USA
Denis Lacombe, European Organization for Research and Treatment of Cancer, Brussels, Belgium
Ronald Levy, Stanford University School of Medicine, Stanford, USA
Timothy Ley, Washington University, St. Louis, USA
Ravindra Majeti, Stanford School of Medicine, Stanford, USA
Charles G. Mullighan, St. Jude Children's Research Hospital, Memphis, USA
Luca Pani, Agenzia Italiana del Farmaco, Rome, Italy
Pier Giuseppe Pelicci, European Institute of Oncology, Milan, Italy
Klaus Rajewsky, Max Delbrück Center for Molecular Medicine, Berlin, Germany
Alessandro Rambaldi, A.O. Papa Giovanni XXIII, Bergamo, Italy
Davide Rossi, Università degli Studi del Piemonte Orientale, Novara, Italy
Margaret A. Shipp, Dana - Farber Cancer Institute, Boston, USA
Reiner Siebert, University of Kiel, Kiel, Germany
Louis M. Staudt, National Cancer Institute, NIH, Bethesda, USA
Stephan Stilgenbauer, University of Ulm, Ulm, Germany
Daniel G. Tenen, Cancer Science Institute of Singapore, Singapore
Christian Thiede, University Hospital Carl Gustav Carus, Dresden, Germany
Maria Teresa Voso, Tor Vergata University, Rome, Italy
Irving Weissman, Stanford University School of Medicine, Stanford, USA
Wyndham Wilson, National Cancer Institute, NIH, Bethesda, USA
Anas Younes, Memorial Sloan Kettering Cancer Center, New York, USA